|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: METTL22 |
Gene summary for METTL22 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | METTL22 | Gene ID | 79091 |
| Gene name | methyltransferase 22, Kin17 lysine | |
| Gene Alias | C16orf68 | |
| Cytomap | 16p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9BUU2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79091 | METTL22 | LZE4T | Human | Esophagus | ESCC | 1.59e-04 | 1.22e-01 | 0.0811 |
| 79091 | METTL22 | LZE7T | Human | Esophagus | ESCC | 1.49e-05 | 2.54e-01 | 0.0667 |
| 79091 | METTL22 | LZE8T | Human | Esophagus | ESCC | 2.30e-03 | 1.15e-01 | 0.067 |
| 79091 | METTL22 | LZE24T | Human | Esophagus | ESCC | 8.92e-09 | 1.83e-01 | 0.0596 |
| 79091 | METTL22 | LZE6T | Human | Esophagus | ESCC | 4.91e-02 | 1.42e-01 | 0.0845 |
| 79091 | METTL22 | P1T-E | Human | Esophagus | ESCC | 4.53e-07 | 2.66e-01 | 0.0875 |
| 79091 | METTL22 | P2T-E | Human | Esophagus | ESCC | 6.38e-24 | 4.14e-01 | 0.1177 |
| 79091 | METTL22 | P4T-E | Human | Esophagus | ESCC | 1.37e-10 | 2.37e-01 | 0.1323 |
| 79091 | METTL22 | P5T-E | Human | Esophagus | ESCC | 4.94e-08 | 1.30e-01 | 0.1327 |
| 79091 | METTL22 | P8T-E | Human | Esophagus | ESCC | 1.02e-11 | 2.66e-01 | 0.0889 |
| 79091 | METTL22 | P9T-E | Human | Esophagus | ESCC | 1.01e-03 | 1.33e-01 | 0.1131 |
| 79091 | METTL22 | P10T-E | Human | Esophagus | ESCC | 1.51e-10 | 1.87e-01 | 0.116 |
| 79091 | METTL22 | P11T-E | Human | Esophagus | ESCC | 1.82e-04 | 2.22e-01 | 0.1426 |
| 79091 | METTL22 | P12T-E | Human | Esophagus | ESCC | 8.74e-17 | 3.06e-01 | 0.1122 |
| 79091 | METTL22 | P15T-E | Human | Esophagus | ESCC | 1.88e-16 | 3.01e-01 | 0.1149 |
| 79091 | METTL22 | P16T-E | Human | Esophagus | ESCC | 3.06e-21 | 3.25e-01 | 0.1153 |
| 79091 | METTL22 | P17T-E | Human | Esophagus | ESCC | 5.87e-03 | 1.61e-01 | 0.1278 |
| 79091 | METTL22 | P20T-E | Human | Esophagus | ESCC | 1.64e-10 | 2.61e-01 | 0.1124 |
| 79091 | METTL22 | P21T-E | Human | Esophagus | ESCC | 4.89e-16 | 1.82e-01 | 0.1617 |
| 79091 | METTL22 | P22T-E | Human | Esophagus | ESCC | 3.98e-17 | 3.49e-01 | 0.1236 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:00434143 | Esophagus | ESCC | macromolecule methylation | 199/8552 | 316/18723 | 3.44e-10 | 9.57e-09 | 199 |
| GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
| GO:000647914 | Esophagus | ESCC | protein methylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
| GO:000821314 | Esophagus | ESCC | protein alkylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
| GO:001802214 | Esophagus | ESCC | peptidyl-lysine methylation | 79/8552 | 131/18723 | 5.17e-04 | 2.86e-03 | 79 |
| GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
| GO:00064797 | Oral cavity | OSCC | protein methylation | 92/7305 | 181/18723 | 7.86e-04 | 4.26e-03 | 92 |
| GO:00082137 | Oral cavity | OSCC | protein alkylation | 92/7305 | 181/18723 | 7.86e-04 | 4.26e-03 | 92 |
| GO:00434142 | Oral cavity | OSCC | macromolecule methylation | 149/7305 | 316/18723 | 1.82e-03 | 8.60e-03 | 149 |
| GO:00322591 | Oral cavity | OSCC | methylation | 168/7305 | 364/18723 | 3.03e-03 | 1.31e-02 | 168 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| METTL22 | SNV | Missense_Mutation | novel | c.209N>C | p.Arg70Thr | p.R70T | Q9BUU2 | protein_coding | tolerated(0.2) | benign(0.001) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| METTL22 | SNV | Missense_Mutation | novel | c.377N>C | p.Arg126Thr | p.R126T | Q9BUU2 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| METTL22 | SNV | Missense_Mutation | rs201872412 | c.667N>A | p.Ala223Thr | p.A223T | Q9BUU2 | protein_coding | tolerated(0.31) | benign(0.029) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| METTL22 | SNV | Missense_Mutation | c.1107N>T | p.Lys369Asn | p.K369N | Q9BUU2 | protein_coding | deleterious(0.03) | benign(0.001) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
| METTL22 | SNV | Missense_Mutation | rs372668884 | c.1198N>A | p.Ala400Thr | p.A400T | Q9BUU2 | protein_coding | deleterious(0.03) | possibly_damaging(0.57) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| METTL22 | SNV | Missense_Mutation | c.986N>G | p.Thr329Arg | p.T329R | Q9BUU2 | protein_coding | deleterious(0) | probably_damaging(0.93) | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| METTL22 | SNV | Missense_Mutation | novel | c.949N>T | p.Leu317Phe | p.L317F | Q9BUU2 | protein_coding | deleterious(0) | benign(0.209) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| METTL22 | SNV | Missense_Mutation | novel | c.149T>C | p.Phe50Ser | p.F50S | Q9BUU2 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| METTL22 | SNV | Missense_Mutation | rs376519641 | c.922G>A | p.Asp308Asn | p.D308N | Q9BUU2 | protein_coding | deleterious(0.05) | possibly_damaging(0.833) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| METTL22 | insertion | In_Frame_Ins | novel | c.984_985insATT | p.Cys328_Thr329insIle | p.C328_T329insI | Q9BUU2 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |